LOVE.V Cannara Biotech Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
12:58
Jan 27
Jan 27
Watch Cannara's $1.7M share-based compensation
The author flags Cannara's $1.7M share-based compensation as not great and something to watch in future quarters. He believes it is related to the resolution of convertible debentures this quarter and Q4 bonuses, suggesting it may be partly one-time.
MED
16:45
Jan 26
Jan 26
Cannara will melt up to low $2 after record results
The author argues Cannara Biotech will melt up and establish a base in the low $2 range. They cite record Q1 results with $1M net income and attribute the YoY decline to likely Q4 executive compensation. The market's positive reaction supports the view.
HIGH
13:08
Jan 26
Jan 26
Solid Q1 with revenue growth and improving balance sheet
The author judges Cannara Biotech's Q1 FY2026 report as another solid result and says the company is moving in the right direction. The bullish view rests on increasing revenues, good margins, and a balance sheet where cash and receivables now cover current liabilities. The main stated concern is high share-based compensation, which the author attributes to Q4 bonuses and will monitor. No specific catalyst or time horizon is stated.
MED
About LOVE.V Investor Commentary
Across the available history and selected sources, Buzzberg tracks LOVE.V (Cannara Biotech Inc.) across 1 sources: 2 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 67% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: u/Forest_City_Frolfer, u/NoOcelot.